277 related articles for article (PubMed ID: 23259395)
21. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
Knutson KL; Disis ML
Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
[TBL] [Abstract][Full Text] [Related]
22. [Development for a novel cancer vaccine].
Tsunoda T
Gan To Kagaku Ryoho; 2004 Dec; 31(13):2095-9. PubMed ID: 15628750
[TBL] [Abstract][Full Text] [Related]
23. [Immune monitoring and cancer vaccine].
Wada H; Doki Y; Nakayama E
Nihon Rinsho; 2012 Dec; 70(12):2183-8. PubMed ID: 23259394
[TBL] [Abstract][Full Text] [Related]
24. [Current status and prospects of cancer vaccine therapy].
Mine T; Terazaki Y; Itoh K
Nihon Rinsho; 2011 Sep; 69(9):1651-6. PubMed ID: 21922769
[TBL] [Abstract][Full Text] [Related]
25. Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.
Palermo B; Del Bello D; Sottini A; Serana F; Ghidini C; Gualtieri N; Ferraresi V; Catricalà C; Belardelli F; Proietti E; Natali PG; Imberti L; Nisticò P
Cancer Res; 2010 Sep; 70(18):7084-92. PubMed ID: 20823160
[TBL] [Abstract][Full Text] [Related]
26. Molecular pathological approaches to human tumor immunology.
Sato N; Hirohashi Y; Tsukahara T; Kikuchi T; Sahara H; Kamiguchi K; Ichimiya S; Tamura Y; Torigoe T
Pathol Int; 2009 Apr; 59(4):205-17. PubMed ID: 19351363
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
Correale P; Del Vecchio MT; La Placa M; Montagnani F; Di Genova G; Savellini GG; Terrosi C; Mannucci S; Giorgi G; Francini G; Cusi MG
J Immunother; 2008; 31(2):132-47. PubMed ID: 18481383
[TBL] [Abstract][Full Text] [Related]
28. Tumor vaccine: current trends in antigen specific immunotherapy.
Baral R
Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903
[TBL] [Abstract][Full Text] [Related]
29. Antitumor vaccination using peptide based vaccines.
Eisenbach L; Bar-Haim E; El-Shami K
Immunol Lett; 2000 Sep; 74(1):27-34. PubMed ID: 10996624
[TBL] [Abstract][Full Text] [Related]
30. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic cancer vaccines.
Morris LF; Ribas A
Surg Oncol Clin N Am; 2007 Oct; 16(4):819-31, ix. PubMed ID: 18022546
[TBL] [Abstract][Full Text] [Related]
32. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma.
Papewalis C; Wuttke M; Jacobs B; Domberg J; Willenberg H; Baehring T; Cupisti K; Raffel A; Chao L; Fenk R; Seissler J; Scherbaum WA; Schott M
Horm Metab Res; 2008 Feb; 40(2):108-16. PubMed ID: 18283628
[TBL] [Abstract][Full Text] [Related]
33. Immunogenic HER-2/neu peptides as tumor vaccines.
Baxevanis CN; Sotiriadou NN; Gritzapis AD; Sotiropoulou PA; Perez SA; Cacoullos NT; Papamichail M
Cancer Immunol Immunother; 2006 Jan; 55(1):85-95. PubMed ID: 15948002
[TBL] [Abstract][Full Text] [Related]
34. Telomerase as a universal tumor antigen for cancer vaccines.
Beatty GL; Vonderheide RH
Expert Rev Vaccines; 2008 Sep; 7(7):881-7. PubMed ID: 18767939
[TBL] [Abstract][Full Text] [Related]
35. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
Sawada Y; Nakatsura T
Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
[TBL] [Abstract][Full Text] [Related]
36. [General principles and first clinical trials of therapeutic vaccines against cancer].
Baurain JF; Van der Bruggen P; Van den Eynde BJ; Coulie PG; Van Baren N
Bull Cancer; 2008 Mar; 95(3):327-35. PubMed ID: 18390413
[TBL] [Abstract][Full Text] [Related]
37. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
38. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine.
Noguchi M; Sasada T; Itoh K
Cancer Immunol Immunother; 2013 May; 62(5):919-29. PubMed ID: 23197273
[TBL] [Abstract][Full Text] [Related]
39. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy in non-renal carcinomas.
Keilholz U
Urologe A; 2004 Sep; 43 Suppl 3():S138-40. PubMed ID: 15148577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
